Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

被引:187
作者
Millan, MJ [1 ]
Lejeune, F [1 ]
Gobert, A [1 ]
机构
[1] Ctr Rech Croissy, Inst Rech Servier, Dept Psychopharmacol, F-78290 Croissy Sur Seine, France
关键词
antidepressant; depression; dopamine; frontal cortex; monoamines; mood; noradrenaline; selective serotonin reuptake inhibitor; serotonin; tricyclic;
D O I
10.1177/026988110001400202
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The frontal cortex (FCX) plays a key role in processes that control mood, cognition and motor behaviour, functions which are compromised in depression, schizophrenia and other psychiatric disorders. In this regard, there is considerable evidence that a perturbation of monoaminergic input to the FCX is involved in the pathogenesis of these states. Correspondingly, the modulation of monoaminergic transmission in the FCX and other corticolimbic structures plays an important role in the actions of antipsychotic and antidepressant agents. In order to further understand the significance of monoaminergic systems in psychiatric disorders and their treatment, it is essential to characterize mechanisms underlying their modulation. Within this framework, the present commentary focuses on our electrophysiological and dialysis analyses of the complex and reciprocal pattern of auto- and heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX. The delineation of such interactions provides a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, noradrenaline and serotonin in FCX. Moreover, it also generates important insights into strategies for the potential improvement in the therapeutic profiles of antidepressant agents.
引用
收藏
页码:114 / 138
页数:25
相关论文
共 386 条
[1]   Regulation of the release of 5-hydroxytryptamine in the median raphe nucleus of the rat by catecholaminergic afferents [J].
Adell, A ;
Artigas, F .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (07) :2305-2311
[2]  
Aghajanian G K, 1988, SEROTONIN RECEPTORS, P226
[3]   Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [J].
Agid, O ;
Lerer, B .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (01) :55-56
[4]   Mianserin, a 5-HT2a/2c and alpha(2) antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors [J].
Aizenberg, D ;
Gur, S ;
Zemishlany, Z ;
Granek, M ;
Jeczmien, P ;
Weizman, A .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (03) :210-214
[5]  
ANDERSSON JL, 1994, N-S ARCH PHARMACOL, V349, P236
[6]   Buspirone: Future directions [J].
Apter, JT ;
Allen, LA .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (01) :86-93
[7]   (R)-8-OH-DPAT PREFERENTIALLY INCREASES DOPAMINE RELEASE IN RAT MEDIAL PREFRONTAL CORTEX [J].
ARBORELIUS, L ;
NOMIKOS, GG ;
HACKSELL, U ;
SVENSSON, TH .
ACTA PHYSIOLOGICA SCANDINAVICA, 1993, 148 (04) :465-466
[8]   Catecholamine regulation of the prefrontal cortex [J].
Arnsten, AFT .
JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (02) :151-162
[9]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[10]  
Audinot V, 1998, J PHARMACOL EXP THER, V287, P187